Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Table 1 Patient demographics and baseline characteristics

Characteristic	Value (N = 80)
Median age, years (range)	60.0 (34–84)
Sex, n (%)
Male	63 (79)
Female	17 (21)
Race
White, n (%)	72 (90)
Black, n (%)	1 (1)
Asian, n (%)	1 (1)
Other	3 (4)
Information missing	3 (4)
Ethnicity
Hispanic or Latino	5 (6)
Not Hispanic or Latino	67 (84)
Not stated	2 (3)
Unknown	6 (8)
Variant HCL, n (%)	3 (4)
Splenectomy, n (%)	5 (6)
Number of prior systemic therapies, median (range)	3 (2–11)
> 3 prior lines, n (%)	39 (49)
Baseline hemoglobin, g/dL, median (range)	11.1 (6.5–16.3)
Baseline neutrophil count, × 10³/µL, median (range)	0.81 (0.1–6.2)
Baseline platelet count, × 10³/µL, median (range)	68.0 (6.0–350.0)
Prior cancer therapy, n (%)
PNA	80 (100)
Rituximab	60 (75)
BRAF inhibitor	14 (18)
Interferon-α	20 (25)
Other	8 (10)
Unfit for PNA re-treatment, n (%)	30 (38)
At risk of infection^a	20 (25)
Active infection^b	19 (24)
Patients refractory to PNA,^c n (%)	39 (49)
PNA monotherapy^d	29 (36)
PNA + rituximab^e	15 (19)

HCL hairy cell leukemia, OR overall response, PNA purine nucleoside analog
^aPatients whose baseline absolute neutrophil count was < 0.5 × 10³/µL
^bPatients whose medical history included a serious infection or febrile neutropenia marked as ‘ongoing’ or ending after the first dose of moxetumomab
^cPatients whose HCL was refractory to any line of PNA. Note: A patient was counted as having HCL refractory to PNA monotherapy and/or PNA + rituximab
^dPatients who did not achieve an OR or who achieved an OR lasting < 1 year
^ePatients who did not achieve an OR or who achieved an OR lasting < 2 years

ISSN: 1756-8722